Ubiquitylation: Caught in the act
Most processes in the cell must be strictly controlled to ensure that they occur only when and where they should. The proteins that carry out these processes are often regulated by modifying them so as to turn them on or off, or to influence their interactions with other proteins. One such modification is ubiquitin, a small protein that can be linked to target proteins to regulate their behaviour. A trio of enzymes, called E1, E2 and E3, are responsible for activating a ubiquitin molecule and then attaching it to a target protein in a process known as ubiquitylation (Figure 1).
By bringing together a target protein with activated ubiquitin, the E3 enzyme catalyses the transfer of this ubiquitin to a specific amino acid residue within the target (a lysine) (Komander and Rape, 2012). However, the details of this process are not well understood. Now, in eLife, a group led by Brenda Schulman, of the St Jude Children’s Research Hospital in Memphis, and Brian Kuhlman, of the University of North Carolina at Chapel Hill, report that they have used structural and biochemical assays to explore how an essential E3 enzyme modifies specific residues in target proteins (Kamadurai et al., 2013).
Schulman, Kuhlman and co-workers—including Hari Kamadurai as first author—have captured the moment when Rsp5, an E3 enzyme that is essential in yeast, transfers a ubiquitin molecule to a lysine residue within a target protein called Sna3. E3s comprise a large class of enzymes, with more than 600 members in human cells; Rsp5 belongs to the HECT family of E3 enzymes, which can regulate essential transcription factors, intracellular trafficking, or the cellular response to stress (Rotin and Kumar, 2009). Accordingly, mutations in genes encoding HECT E3s can lead to several diseases, among them inflammatory syndromes or hypertension.
The catalytic portion of the HECT E3 enzyme, which adds ubiquitin to the target protein, is called the HECT domain; this region is composed of two lobes—the N-lobe and the C-lobe—that are connected by a flexible linker. Intriguingly, previous research suggested that these lobes might adopt a variety of positions with respect to each other during the attachment of ubiquitin to the target protein. Moreover, it appeared that there might be a considerable distance between the relevant lysine in the target protein and the active (catalytic) site of the HECT domain (Verdecia et al., 2003; Kamadurai et al., 2009). These details have frustrated attempts to model how HECT E3s might transfer ubiquitin to a target protein and, in particular, to a specific residue in that target.
The C-lobe of the HECT domain contains a cysteine residue, which is charged with ubiquitin through a thioester bond to create an essential catalytic intermediate also found in a few other classes of E3 enzymes (Wenzel et al., 2011). The C-lobe also provides a site for non-covalent interaction with ubiquitin: this stabilizes the covalent bond between ubiquitin and the E3 enzyme, and it also helps to transfer ubiquitin to the target protein (Kamadurai et al., 2009; Maspero et al., 2013). The N-lobe possesses a key binding site for E2 enzymes, which load ubiquitin onto the active site of the HECT E3 (Figure 1) (Kamadurai et al., 2009). Using a bivalent crosslinker attached to a specific site in a target peptide, Kamadurai et al. revealed that the transfer of ubiquitin from the E3 enzyme to the target protein coincides with a dramatic re-organization of the HECT domain, with the C-lobe swinging through an angle of ∼130° to place the catalytic centre next to the target lysine.
In addition to closing the gap between the active site and the modified lysine, this rearrangement produces a large region of interaction between the two lobes of the HECT domain that serves important functions. First, it clamps down on the flexible C-terminal tail of ubiquitin, thereby orienting the thioester bond for nucleophilic attack by the lysine on the target protein. It also leads to formation of a composite active site that contains both the catalytic cysteine in the C-lobe and an acidic residue of the N-lobe that might orient or deprotonate the substrate lysine. Lastly, the arrangement of the catalytically engaged HECT domain restricts the flexibility of the active site relative to the portion of the E3 that associates with the target protein, a feature that enables the enzyme to prioritize the lysine that is modified in vivo. Other E3 enzymes have recently been seen to tether the activated ubiquitin during catalysis (Saha et al., 2011; Wickliffe et al., 2011; Dou et al., 2012; Plechanovová et al., 2012; Pruneda et al., 2012), and the orientation of the catalytic site relative to motifs that can interact with target proteins might also help to determine how E3s with different catalytic domains select lysines to modify on target proteins (Wu et al., 2003; Williamson et al., 2011). The present findings therefore raise the exciting hypothesis that very different classes of E3 enzymes evolved similar mechanisms to modify target proteins rapidly and specifically.
In addition to adding a single ubiquitin to a lysine within a target protein, HECT E3s can also assemble polymeric ubiquitin chains that are connected through one of a few dedicated lysines of ubiquitin (lysines 29, 48 or 63) (Rotin and Kumar, 2009). Previous studies have found that the C-lobe of the HECT domain can determine which one of these lysines is used in chain formation (Kim and Huibregtse, 2009), while Kamadurai et al. point to a requirement for N-lobe residues in coordinating this process. It will be interesting to see if HECT E3s can also be ‘caught in the act’ of assembling a chain, as this could reveal how multiple interactions contributed by several domains of the enzyme establish catalytic efficiency and specificity.
Collectively, these new insights underscore the importance of structural rearrangements for catalysis, a phenomenon that might be referred to as macromolecular juggling (Lorenz et al., 2013). Pessimists might view these idiosyncrasies of ubiquitylation reactions as posing challenges to the identification of small molecules that can target disease-relevant E3s. Optimists, however, might see the architectural changes that occur during ubiquitylation as providing opportunities for drug discovery. Hopefully, innovative approaches such as those documented in this study will help to harness the potential of ubiquitylation enzymes for therapeutic purposes.
References
-
The ubiquitin codeAnnu Rev Biochem 81:203–229.https://doi.org/10.1146/annurev-biochem-060310-170328
-
Physiological functions of the HECT family of ubiquitin ligasesNat Rev Mol Cell Biol 10:398–409.https://doi.org/10.1038/nrm2690
Article and author information
Author details
Publication history
- Version of Record published: August 8, 2013 (version 1)
Copyright
© 2013, Meyer and Rape
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 324
- Page views
-
- 45
- Downloads
-
- 0
- Citations
Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Biochemistry and Chemical Biology
- Structural Biology and Molecular Biophysics
The complex of methyltransferase-like proteins 3 and 14 (METTL3-14) is the major enzyme that deposits N6-methyladenosine (m6A) modifications on messenger RNA (mRNA) in humans. METTL3-14 plays key roles in various biological processes through its methyltransferase (MTase) activity. However, little is known about its substrate recognition and methyl transfer mechanism from its cofactor and methyl donor S-adenosylmethionine (SAM). Here, we study the MTase mechanism of METTL3-14 by a combined experimental and multiscale simulation approach using bisubstrate analogues (BAs), conjugates of a SAM-like moiety connected to the N6-atom of adenosine. Molecular dynamics simulations based on crystal structures of METTL3-14 with BAs suggest that the Y406 side chain of METTL3 is involved in the recruitment of adenosine and release of m6A. A crystal structure with a BA representing the transition state of methyl transfer shows a direct involvement of the METTL3 side chains E481 and K513 in adenosine binding which is supported by mutational analysis. Quantum mechanics/molecular mechanics (QM/MM) free energy calculations indicate that methyl transfer occurs without prior deprotonation of adenosine-N6. Furthermore, the QM/MM calculations provide further support for the role of electrostatic contributions of E481 and K513 to catalysis. The multidisciplinary approach used here sheds light on the (co)substrate binding mechanism, catalytic step, and (co)product release, and suggests that the latter step is rate-limiting for METTL3. The atomistic information on the substrate binding and methyl transfer reaction of METTL3 can be useful for understanding the mechanisms of other RNA MTases and for the design of transition state analogues as their inhibitors.
-
- Biochemistry and Chemical Biology
- Developmental Biology
Imidacloprid is a global health threat that severely poisons the economically and ecologically important honeybee pollinator, Apis mellifera. However, its effects on developing bee larvae remain largely unexplored. Our pilot study showed that imidacloprid causes developmental delay in bee larvae, but the underlying toxicological mechanisms remain incompletely understood. In this study, we exposed bee larvae to imidacloprid at environmentally relevant concentrations of 0.7, 1.2, 3.1, and 377 ppb. There was a marked dose-dependent delay in larval development, characterized by reductions in body mass, width, and growth index. However, imidacloprid did not affect on larval survival and food consumption. The primary toxicological effects induced by elevated concentrations of imidacloprid (377 ppb) included inhibition of neural transmission gene expression, induction of oxidative stress, gut structural damage, and apoptosis, inhibition of developmental regulatory hormones and genes, suppression of gene expression levels involved in proteolysis, amino acid transport, protein synthesis, carbohydrate catabolism, oxidative phosphorylation, and glycolysis energy production. In addition, we found that the larvae may use antioxidant defenses and P450 detoxification mechanisms to mitigate the effects of imidacloprid. Ultimately, this study provides the first evidence that environmentally exposed imidacloprid can affect the growth and development of bee larvae by disrupting molting regulation and limiting the metabolism and utilization of dietary nutrients and energy. These findings have broader implications for studies assessing pesticide hazards in other juvenile animals.